A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2006-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the efficacy, safety and tolerability of DPP-IV Inhibitor in patients with type 2 diabetes receiving a stable dose of metformin. The anticipated time on study treatment is 3-12 months and the target sample size is 100-500 individuals.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Dipeptidyl-Peptidase IV Inhibitors; Metformin

Criteria

Inclusion Criteria:

• adult patients 18-75 years of age;

• type 2 diabetes;

• stable metformin therapy for >=3 months before screening.

Exclusion Criteria:

• women who are pregnant, breast-feeding, or not using an adequate contraceptive method;

• type 1 diabetes;

• any anti-hyperglycemic medication other than metformin in the last 3 months.